wve-006
Nucleic acidexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 14, 2023 (NCT06186492)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Alpha-1-antiproteinaseANTISENSE INHIBITOR
SERPINA1 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06405633 | Phase 1/Phase 2 (Phase 2) | Jul 19, 2024 | Wave Life Sciences |
| NCT06186492 | Phase 1 | Nov 14, 2023 | Wave Life Sciences |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Wave Life Sciences | For profit | 2 | 2 | 2 | 2023 |
1 organizations
Page 1 / 1